Accelerate to discover

Homepage>Discover>Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Back to filter

Aug 16, 2024

We invite you to learn more about MERSCOPE Ultra Platform. Webinar featuring Rob Mathis (Global Instrument Product...

Webinar recording: Exploring Platelet Adhesion and Aggregation Under Physiological Shear Flow

Aug 14, 2024

In this webinar, Dr. Mohammad Ekhlak of Banaras Hindu University will share data and insights from the Center for...

Webinar recording : BioFlux, the gold standard for Platelet Biology and Thrombosis research

Jul 29, 2024

Thrombosis, the underlying cause of major fatal conditions like ischemic stroke and myocardial infarction, poses a...

Automatic, Real Time Acquisition of Bioluminescent Kinetic Curves

Jun 27, 2024

Watch this pre-recorded webinar with Dr. Andrew Van Praagh to learn how our new Aura software feature —Kinetics—...

Oct 4, 2024

Hypoxia in the Tumor Immune Microenvironment (TIME)

Jun 6, 2024

Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD...

Exosome-Mediated Delivery of Small Molecules, RNA & DNA for Development of Novel Cancer Therapeutics

Jun 3, 2024

Disha Moholkar of University of Louisville's Gupta Lab
Tuesday, June 11, 2024, 6:30 PM
...

Have you missed any recent Cytek webinars? Watch webinars and product tutorial videos at any time

Apr 23, 2024

Have you missed any recent Cytek webinars? Watch webinars and product tutorial videos at any time at Cytek website....

Oct 4, 2024

Webinar: Multimodal Assessment of Hypoxia in Tumors: From the Lab to the Clinic

Apr 2, 2024

25 April 2024, 4PM CET
This webinar will be of interest to multiple profiles in the community of biomedical
...

Show all topics (10)

Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Oct 13, 2016

Nabil Ahmed, M.D., M.P.H. Associate Professor of Pediatrics, Baylor College of Medicine (USA).

Robust CAR design and sensitive yet realistic functional testing will be required in order to improve the efficacy of CAR T cell therapies targeting solid tumors. We have used the xCELLigence Real-Time Cell Analyzer as a high-throughput platform to test multiple CAR components including extracellular domains (including bi-specifics), signaling endo-domains, as well as next-generation CAR T cell products that are inherently resistant to checkpoint blockade. This platform has proven very sensitive to subtle yet longitudinally meaningful differences in CAR design, and has made it possible to evaluate T cell products in a "stress test" that is more representative of early phase trial requirements.

Register now

Webinar

Related technologies: Real-time, label free cell analysis

Get more info